We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ESPR market cap is 394.16M. The company's latest EPS is USD -1.1307 and P/E is -1.88.
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 18.82M | 24.33M | 25.79M | 33.97M | 32.25M |
| Operating Income | -42.51M | -48.61M | -37.06M | -27.53M | -42.37M |
| Net Income | -55.49M | -61.72M | -49.94M | -41.25M | -56.34M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 148.36M | 227.55M | 78.45M | 75.48M | 116.33M |
| Operating Income | -93.1M | -121.4M | -226.73M | -179.5M | -155.56M |
| Net Income | -97.17M | -143.55M | -269.11M | -233.66M | -209.25M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 247.94M | 251.82M | 234.63M | 221.31M | 205.8M |
| Total Liabilities | 571.72M | 581.48M | 606.6M | 631.31M | 660.79M |
| Total Equity | -323.78M | -329.66M | -371.98M | -410M | -454.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 214.45M | 353.26M | 381.59M | 247.94M | 205.8M |
| Total Liabilities | 194.5M | 449.39M | 578.53M | 571.72M | 660.79M |
| Total Equity | 19.95M | -96.13M | -196.94M | -323.78M | -454.99M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -174.83M | -54.36M | -79.11M | -98.43M | -135.49M |
| Investing | 8.1M | 25M | 42.5M | 42.5M | 42.5M |
| Financing | 32.61M | 49.49M | 50.3M | 45.99M | 50.46M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -70.34M | -85.18M | -263.81M | -174.83M | -135.49M |
| Investing | 64.23M | 21.36M | -50.48M | 8.1M | 42.5M |
| Financing | 136.2M | 201.73M | 268.22M | 32.61M | 50.46M |
| Market Cap | 394.16M |
| Price to Earnings Ratio | -1.88 |
| Price to Sales Ratio | 3.39 |
| Price to Cash Ratio | 4.79 |
| Price to Book Ratio | -0.87 |
| Dividend Yield | - |
| Shares Outstanding | 185.05M |
| Average Volume (1 week) | 7.01M |
| Average Volume (1 Month) | 8.36M |
| 52 Week Change | 30.67% |
| 52 Week High | 3.40 |
| 52 Week Low | 0.70 |
| Spread (Intraday) | 0.01 (0.47%) |
| Company Name | Esperion Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.esperion.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
